ReviewDrugs & therapy perspectives : for rational drug selection and use2022
RTS,S/AS01 malaria vaccine (Mosquirix
Review in Drugs & therapy perspectives : for rational drug selection and use, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Determinants of Malaria Vaccine Acceptance: A Systematic Review and Meta-Analysis of Awareness, Acceptance, Hesitancy, and Willingness to Pay.Immunity, inflammation and disease · 2025Pooled it
- Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial.Frontiers in immunology · 2023Trial
- Suboptimal uptake of the malaria vaccine in Sudan: what's behind the blinds?Malaria journal · 2026Article
- An age-structured mathematical model to assess the combined effects of vaccine and non-vaccine interventions on malaria transmission and burden.Infectious Disease Modelling · 2026Article
- Estimating the impact of the RTS,S/AS01 malaria vaccine in Benin: A mathematical modelling study.PLOS global public health · 2026Article
- The challenge of one billion adjuvanted vaccine doses: evaluating scalability, sustainability, and supply capacity of Quillaja saponin QS-21 for large-scale vaccine demand.Frontiers in immunology · 2026Review
- The characterization of a rhamnosylated triterpenic saponin fromFrontiers in pharmacology · 2026Article
- Priming or Boosting Plasmodium falciparum Transmission-Blocking Responses With Recombinant Vaccines or Gametocyte Extract.The Journal of infectious diseases · 2025Article
- Fast and Straightforward Lipid Quantification in Pharmaceutical Compositions Using NMR.ACS omega · 2025Article
- Emerging Role of Splenic Macrophage in Malaria Pathogenesis and Immunity.Immunity, inflammation and disease · 2025Review
- Designing a multi-epitope vaccine against the midgut-specific fibrinogen-related protein 1(FREP1) of Anopheles stephensi to enhance protection against the malaria parasite: a step beyond traditional vaccine development approaches.Biotechnology letters · 2025Article
- Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025Review
- Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication.Ethiopian journal of health sciences · 2025Review
- Pfs16: A Key Parasitophorous Vacuole Membrane Protein Crucial for Malaria Parasite Development and Transmission.The protein journal · 2025Review
- One Health adjuvant selection for vaccines against zoonotic infections.Exploration of medicine · 2025Article
- Antimalarial Drug Discovery from Natural and Synthetic Sources.Current medicinal chemistry · 2025Review
- Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions.Clinical pharmacology : advances and applications · 2025Review
- Search continues: Exploring immunoinformatics platforms for designing an effective multiepitope malaria vaccine candidate.Biotechnologia · 2025Article
- Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.Human vaccines & immunotherapeutics · 2024Review
- Recent Advances in the Treatment of Malaria.Pharmaceutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RTS,S/AS01 (Mosquirix Supplementary Information: The online version contains supplementary material available at 10.1007/s40267-022-00937-3.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.